Search clinical trials for: Trametinib Dimethyl Sulfoxide

Total 1199 results

Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors

Glioblastoma | Astrocytoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Pleomorphic Xanthoastrocytoma | Ganglioglioma | Pleomorphic Xanthoastrocytoma | Diffuse Astrocytoma | Anaplastic Oligodendroglioma | Pilocytic Astrocytoma | Gangliocytoma | Central Neurocytoma | Oligodendroglioma, Childhood and other conditions

United States, Italy, Japan, Germany, Spain, France, Canada, Australia, Brazil, Israel, Russian Federation, Argentina, United Kingdom, Finland, Belgium, Denmark, Czechia, Sweden, Switzerland, Netherlands
Eli Lilly and Company

Completed

A Study of LY2875358 in Participants With Advanced Cancer

Advanced Cancer

United States
Hospital Universitario Getafe

Completed

Treatment of Thromboangiitis Obliterans (Buerguer's Disease) With Bosentan

Thromboangiitis Obliterans

Spain
DEKK-TEC, Inc.
National Cancer Institute (NCI)

Completed

DM-CHOC-PEN Plus Radiation for Brain Tumors

Advanced Cancer

United States
Novartis Pharmaceuticals

Completed

Treatment Patterns and Outcomes of Targeted Therapy and Immunotherapy Among BRAF-Positive Melanoma Patients Treated in the Adjuvant Setting and Among BRAF-Positive Metastatic Melanoma Patients With Low Tumor Burden

Metastatic Melanoma

United States
Novartis Pharmaceuticals

Completed

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma

United States, France, Taiwan, Canada, Italy, Singapore, Belgium, Spain, Israel
DEKK-TEC, Inc.

No longer available

A Phase I Trial of DM-CHOC-PEN in Adolescent and Young Adult (AYA) Subjects With Advanced Cancers

Advanced Cancer

United States
IRCCS Centro Neurolesi "Bonino-Pulejo"

Recruiting

Effects of Dimethyl Fumarate on Cognitive Performance and Brain Abnormalities in Multiple Sclerosis.

Multiple Sclerosis

Italy
Brigham and Women's Hospital
EMD Serono

Withdrawn

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

Multiple Sclerosis

United States
Glaceum
Seoul National University Hospital

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics and Food Effect of HSG4112 in High Doses

Obesity

Korea, Republic of
Glaceum
Seoul National University Hospital

Completed

A Study to Investigate the Effect of Food on the Pharmacokinetics of HSG4112

Obesity

Korea, Republic of
St. Justine's Hospital
CHU de Quebec-Universite Laval; Montreal Children's Hospital of the MUHC

Active, not recruiting

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Low-grade Glioma | Plexiform Neurofibroma | Central Nervous System Glioma

Canada
GlaxoSmithKline

Completed

Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma

Solid Tumours

United States
GlaxoSmithKline

Completed

GSK1120212 Food-effect Study

Cancer

United States
Panbela Therapeutics, Inc.

Completed

Study of SBP-101 in Pancreatic Cancer

Pancreatic Cancer | Ductal Adenocarcinoma of the Pancreas

United States, Australia
Abramson Cancer Center of the University of Pennsylvania

Completed

Dabrafenib, Trametinib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma (BAMM)

Advanced BRAF Mutant Melanoma

United States
GlaxoSmithKline

Withdrawn

Pharmacokinetics of Single and Repeat Oral Doses of Trametinib in Chinese Subjects With Solid Tumours

Cancer
Geisinger Clinic

Not yet recruiting

Pneumonia Vaccine Education Intervention Study (PVI)

Pneumonia, Pneumococcal | Vaccine
Anna Raciborska
Maria Sklodowska-Curie National Research Institute of Oncology; Łukasiewicz... and other collaborators

Recruiting

Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients (TRAM)

Histiocytosis

Poland
Shanghai Chest Hospital

Completed

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Non Small Cell Lung Cancer

China
Region Skane
Novartis

Active, not recruiting

Treatment of NF1-related Plexiform Neurofibroma With Trametinib (plexifpc)

Child | Neurofibromatosis 1 | Neurofibroma, Plexiform

Sweden
Glaceum
Seoul National University Hospital; Korea University Anam Hospital; Seoul National... and other collaborators

Completed

A Study to Evaluate the Safety and Efficacy of HSG4112 in Overweight and Obese Patients

Obesity

Korea, Republic of
Glaceum
Seoul National University Hospital; Kyungpook National University Hospital

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Characteristics, and Food Effect of HSG4112

Obesity

Korea, Republic of
Biogen

Completed

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis (CONFIRM)

Relapsing-Remitting Multiple Sclerosis

United States, Croatia, Bulgaria, Czech Republic, France, Mexico, Poland, Spain, Germany, Belarus, Estonia, Latvia, Romania, Ukraine, Israel, New Zealand, Slovakia, Greece, India, Serbia, Ireland, Costa Rica, Canada, Belgium, Macedonia,... and more
Glaceum

Not yet recruiting

A Study to Assess the Efficacy and Safety of Vutiglabridin in Early Parkinson's Disease Patients

Parkinson Disease
Mallinckrodt

Withdrawn

IK-1001 (Sodium Sulfide (Na2S) for Injection) in Subjects With Acute ST-Segment Elevation Myocardial Infarction

ST-Segment Elevation Myocardial Infraction
Anders Svenningsson

Completed

RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis. (RIFUND-MS)

Multiple Sclerosis, Relapsing-Remitting

Sweden
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)

Solid Tumors, KRAS Mutation; SOS1

United States, Netherlands, Germany
Albany Research Institute, Inc.

Completed

Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea (TOMIR)

Rosacea, Erythematotelangiectatic

United States
Novartis Pharmaceuticals

Completed

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Melanoma | Cancer

Taiwan, Thailand, China, Hong Kong, Korea, Republic of
University of California, San Francisco
Novartis Pharmaceuticals; American Cancer Society, Inc.

Terminated

Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States
Kartos Therapeutics, Inc.

Completed

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Acute Myeloid Leukemia | Cancer | Oncology | Advanced Malignancy | Oncology Patients

United States
GlaxoSmithKline

Completed

GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma

Melanoma

United States, Italy, United Kingdom, France, Sweden, Germany, Poland, Australia, Belgium, Austria, Canada, Czechia, Greece, Russian Federation, Ukraine, Norway, Switzerland, New Zealand, Argentina
GlaxoSmithKline

Completed

A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers

Cancer

United States
GlaxoSmithKline

No longer available

Access Study of Trametinib for Subjects With Advanced Unresectable (Stage IIIc) or Distant Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma

Melanoma

France
Washington University School of Medicine
National Comprehensive Cancer Network

Completed

GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer

Mouth Neoplasms | Neoplasms, Oral

United States
Glaceum
Seoul National University Hospital; Kyungpook National University Hospital

Completed

A Study to Investigate the Safety and Pharmacokinetic/Pharmacodynamic Characteristics of HSG4112

Obesity

Korea, Republic of
C4 Therapeutics, Inc.

Recruiting

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and in Combination With Trametinib in Subjects With BRAF V600 Mutant Solid Tumors

Melanoma | NSCLC | Solid Tumors | CRC | ATC

United States, Spain, France
Xynomic Pharmaceuticals, Inc.

Not yet recruiting

XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation (ENHANCE)

Melanoma | Cancer | Colorectal Cancer | Nonsmall Cell Lung Cancer | Thyroid Cancer | BRAF V600 Mutation
University Health Network, Toronto
GlaxoSmithKline

Completed

A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer

Adenocarcinoma | Pancreatic Cancer

Canada
GlaxoSmithKline

Terminated

Phase II Biomarker Study Comparing the Combination of BRAF Inhibitor Dabrafenib With MEK Inhibitor Trametinib Versus the Combination After Monotherapy With Dabrafenib or Trametinib

Melanoma

Spain, France
Centre Leon Berard
Novartis

Completed

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD)

Colorectal Cancer | Metastatic Cancer | Advanced Cancer

France
Grupo Español Multidisciplinar de Melanoma
GlaxoSmithKline

Completed

Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain (DEIS)

Malignant Melanoma Stage IV | Malignant Melanoma Stage IIIc

Spain
GlaxoSmithKline

Completed

Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias

Cancer

United States, France, Germany, Belgium
Pfizer

Completed

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

Breast Neoplasms | Metastatic Breast Cancer

United States
GlaxoSmithKline

Withdrawn

Pharmacokinetics of Repeat Oral Doses of Dabrafenib and the Combination of Dabrafenib and Trametinib in Chinese Subjects With Melanoma

Melanoma
GlaxoSmithKline

Withdrawn

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

Cancer | Metastatic Uveal Melanoma | GNA11 Mutation-positive Metastatic Melanoma | GNAQ Mutation-positive Metastatic Melanoma
GlaxoSmithKline

Completed

Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor

Cancer

Australia, United States
St. Jude Children's Research Hospital
Novartis Pharmaceuticals

Active, not recruiting

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors

Glioma | Neoplasms | Glioblastoma | Neoplasms, Neuroepithelial | Central Nervous System Neoplasms | Brain Cancer | Brain Tumor | Ependymoma | Medulloblastoma | Anaplastic Astrocytoma | Anaplastic Ganglioglioma | Anaplastic Ependymoma | Anaplastic Oligodendroglioma | Pineoblastoma | Recurrent Medulloblastoma | CNS Tumor | Pediatric... and other conditions

United States
Valenta Pharm JSC

Completed

Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma

Pyoderma

Russian Federation

Search clinical trials for: Trametinib Dimethyl Sulfoxide

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations